Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Medpace Holdings Inc (MEDP) vs Royal Bank of Canada (RY) Price & Performance

Medpace Holdings IncTrade
Royal Bank of CanadaTrade

Price performance (Past 24H)

Key statistics

Medpace Holdings Inc vs Royal Bank of Canada — how do they compare? Medpace Holdings Inc trades at $605.78 (market cap $16.81B), while Royal Bank of Canada trades at $210.44 (market cap $292.92B). The key difference: Royal Bank of Canada is far larger — about 17.4× Medpace Holdings Inc's market cap, and Royal Bank of Canada pays a 2.36% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals.

MEDPRY
Market Cap
$16.81B$292.92B
Sector
TechnologyFinancials
52-Week High
$620.59$217.87
52-Week Low
$393.42$134.80
Enterprise Value
$16.43B
Dividend Yield
2.36%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Medpace Holdings Inc

MEDP trades at $590.67, up 0.97% on the day, near its consensus price target of $599.57. The stock shows bullish momentum with a golden cross formation and strong institutional interest, while recent Q2 2026 earnings beat estimates with EPS of $4.25 versus $3.98 expected. Revenue growth remains robust, projected to rise from $2.53 billion in 2025 to $2.8 billion in 2026, supporting a premium valuation with a P/E of 35.4.

Outlook is positive given earnings consistency and raised 2026 guidance, but risks include high valuation sensitivity and a shareholder lawsuit investigation. The stock offers growth potential from a strong backlog and net book-to-bill ratio of 1.13x, though investors should monitor legal developments and competitive pressures in medical services.

Royal Bank of Canada

Royal Bank of Canada (RY) trades at $211.08, down 0.17% on the day, with a bullish technical signal from moving averages and a neutral stance from oscillators. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $2.84 exceeding expectations. Revenue grew to $66.53B in 2025, and net income margin improved to 31.85%. Analyst consensus is mixed, with 43% buy ratings, while recent news highlights insider selling and institutional adjustments to holdings.

RY presents a solid investment case with robust profitability and consistent earnings outperformance, though valuation ratios like P/E of 19.23 and P/B of 3.17 suggest a premium. Risks include high debt levels and macroeconomic sensitivity, but the bullish technical trend and dividend yield support a cautiously optimistic outlook for long-term investors.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Medpace Holdings Inc

Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.

Read more on MEDP

About Royal Bank of Canada

Royal Bank of Canada is one of the two largest banks in Canada. It is a diversified financial services company, offering personal and commercial banking, wealth-management services, insurance, corporate banking, and capital markets services. The bank is concentrated in Canada, with additional operations in the U.S. and other countries.

Read more on RY